DealsAug 6, 2026, 04:33 PM
Arcturus Terminates CSL Seqirus Collaboration; Q2 Net Loss $(23.8)M
AI Summary
Arcturus Therapeutics Holdings Inc. announced the termination of its Collaboration and License Agreement with CSL Seqirus on August 3, 2026, a significant strategic development. For the second quarter of 2026, the company reported a net loss of $(23.8) million on total revenue of $3.0 million, compared to a net loss of $(9.2) million on $28.3 million in revenue for the same period in 2025. The company also entered into a strategic collaboration with Thermo Fisher for the development of ARCT-032, an investigational mRNA therapeutic for cystic fibrosis, with potential services valued up to $80.0 million.
Key Highlights
- Arcturus and CSL Seqirus terminated their Collaboration and License Agreement on August 3, 2026.
- Net loss for Q2 2026 increased to $(23.8) million from $(9.2) million in Q2 2025.
- Total revenue for Q2 2026 decreased to $3.0 million from $28.3 million in Q2 2025.
- Net loss for the six months ended June 30, 2026 was $(50.7) million, up from $(23.3) million in 2025.
- Total revenue for the six months ended June 30, 2026 was $5.0 million, down from $57.7 million in 2025.
- Cash and cash equivalents stood at $191.5 million as of June 30, 2026.
- Research and development expenses decreased to $17.5 million in Q2 2026 from $29.6 million in Q2 2025.
- Entered strategic collaboration with Thermo Fisher for ARCT-032 development, valued up to $80.0 million.
Price Impact
More from ARCT